MEDNAX Announces Acquisition of Perinatology Practice in Texas
20 Octubre 2014 - 6:00AM
Business Wire
Expands Continuum of Women's and Newborn Care
in Houston Market
MEDNAX, Inc., (NYSE: MD) today announced the acquisition of
Houston Perinatal Associates, P.A., a private physician group
practice based in Houston, Texas. The practice will become part of
MEDNAX’s Pediatrix Medical Group division.
Established in 1994, Houston Perinatal Associates consists of
four physicians and 30 other clinical and administrative staff who
provide comprehensive high-risk maternal-fetal medicine services at
The Woman’s Hospital of Texas and 10 satellite perinatal clinics.
The practice provides services including obstetrics and delivery,
ultrasounds, prenatal diagnosis, medical and surgical complications
of pregnancy, as well as the management of multiple gestations. In
addition, the practice provides maternal-fetal medicine services to
three Houston metropolitan area hospitals and one surgery center,
as well as telemedicine services to patients in Lufkin, Texas.
This acquisition extends MEDNAX’s ability to provide a continuum
of care in the Houston market, including neonatal, perinatal,
pediatric cardiology, pediatric hospitalist and anesthesia
services. It also enhances the services MEDNAX provides at The
Woman’s Hospital of Texas, which include perinatal care, neonatal
care at the hospital's Level II and Level III neonatal intensive
care units, pediatric cardiology and, through MEDNAX's American
Anesthesiology division, anesthesia services.
“As a physician-led national medical group, MEDNAX will allow us
to maintain our clinical autonomy while supporting the growth of
our practice and improving office efficiencies in a changing
healthcare environment,” said Brian Kirshon, M.D., who will serve
as medical director for the practice. “We look forward to
collaborating with clinicians across the country on high-risk
maternal-fetal care, and to being part of the research, education
and quality initiatives that are the foundation of the
company.”
The practice was acquired for cash and the transaction is
expected to be immediately accretive to earnings. No additional
terms of the transaction were disclosed.
With this acquisition, eight physician group practices have
become part of MEDNAX in 2014, two as part of Pediatrix Medical
Group and six as part of American Anesthesiology.
ABOUT MEDNAX
MEDNAX, Inc. is a national medical group that comprises the
nation's leading providers of neonatal, anesthesia, maternal-fetal
and pediatric subspecialty services. The Company is reshaping the
delivery of care within its specialties and subspecialties using
evidence-based tools, continuous quality initiatives and clinical
research to enhance patient outcomes and provide high-quality,
cost-effective care. Pediatrix Medical Group, a division of MEDNAX,
was founded in 1979 and includes neonatal physicians who provide
services at more than 360 neonatal intensive care units, and
collaborate with affiliated maternal-fetal medicine, pediatric
cardiology, pediatric critical care and physician subspecialists to
provide a clinical care continuum. Pediatrix is also the nation's
largest provider of newborn hearing screens. American
Anesthesiology, a division of MEDNAX, was established in 2007 and
includes more than 2,150 anesthesiologists and advanced
practitioners who provide anesthesia care to patients in connection
with surgical and other procedures as well as pain management.
MEDNAX, through its affiliated professional corporations, employs
more than 2,550 physicians in 34 states and Puerto Rico. Additional
information is available at www.mednax.com.
Certain statements and information in this press release may be
deemed to contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements may include, but are not limited to, statements relating
to our objectives, plans and strategies, and all statements, other
than statements of historical facts, that address activities,
events or developments that we intend, expect, project, believe or
anticipate will or may occur in the future. These statements are
often characterized by terminology such as “believe”, “hope”,
“may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”,
“estimate”, “project”, “positioned”, “strategy” and similar
expressions, and are based on assumptions and assessments made by
MEDNAX’s management in light of their experience and their
perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. Any forward-looking statements in this press release
are made as of the date hereof, and MEDNAX undertakes no duty to
update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties. Important factors that could cause actual
results, developments, and business decisions to differ materially
from forward-looking statements are described in MEDNAX’s most
recent Annual Report on Form 10-K and its Quarterly Reports on Form
10-Q, including the sections entitled “Risk Factors”, as well
MEDNAX’s current reports on Form 8-K, filed with the Securities and
Exchange Commission.
MEDNAX, Inc.Charles Lynch, 954-384-0175, x-5692Vice President,
Strategy and Investor Relationscharles_lynch@mednax.com
MacDonald, Dettwiler & (NYSE:MDA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
MacDonald, Dettwiler & (NYSE:MDA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024